JSW Steel: Buy or sell? Jefferies sees 15% upside, CLSA remains cautious despite Q1 profitability boost
Brokerages are divided in their views on JSW Steel after the company reported a solid performance in Q1FY26, with rising profitability supported by higher realizations and lower input costs. While Jefferies maintains a bullish stance, CLSA remains cautious, flagging limited near-term upside despite operational tailwinds. Jefferies – Buy | Target: ₹1,200 | Upside: 15%
Jefferies maintained a Buy rating on JSW Steel, projecting a 15% upside from the current market price of ₹1,044.80. The brokerage highlighted a strong Q1FY26, where EBITDA rose 37% YoY and 19% QoQ, beating their estimates by 5%. EBITDA per tonne jumped 33% sequentially to ₹11,300, driven by higher realizations .
Volumes grew 9% YoY , indicating strong demand traction.
Jefferies expects margins to contract in Q2, as Indian spot steel prices are 4% below Q1 averages, but sees this as a temporary dip.
The brokerage also noted that Asian steel spreads are 30% below long-term averages, meaning any recovery could significantly improve profitability. Over the medium term, Jefferies expects a 9% volume CAGR in India between FY25–27, even after trimming FY26–28 EPS estimates by 3–9%. CLSA – Underperform | Target: ₹890 | Downside: 15%
In contrast, CLSA retained its Underperform rating, with a target price of ₹890, implying a 15% downside. While the firm acknowledged that Q1 EBITDA was largely in line, with standalone EBITDA/t improving by ₹1,835 to ₹10,618, it remained cautious on valuation and long-term visibility. Profitability in Q1FY26 was aided by higher steel prices and lower coking coal costs .
Despite a recent dip in steel prices, CLSA expects Q2 earnings to stay stable , supported by continued low input costs and the fading out of FX/shutdown-related expenses .
However, the brokerage stressed that macro triggers and expansion project execution will be key to driving sustainable earnings. Brokerage Summary: Brokerage Rating Target Price (₹) Implied Move from CMP (₹1,044.80) Jefferies Buy 1,200 +15% CLSA Underperform 890 –15% Verdict: A split call on valuation vs growth
While Jefferies sees strong volume growth potential and a favourable cost structure as reasons to stay bullish, CLSA remains cautious due to valuation concerns and execution risks tied to macro and expansion factors. Investors may want to monitor steel price trends, coal input costs, and expansion project updates closely in the coming quarters.
Disclaimer: The brokerage views expressed are based on publicly available research reports and do not constitute investment advice. Readers should consult a certified financial advisor before making any investment decisions.
Ahmedabad Plane Crash
News desk at BusinessUpturn.com
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
The Hill
24 minutes ago
- The Hill
Asian shares rise, buoyed by expectation of more trade pacts after US-Japan tariff deal
MANILA, Philippines (AP) — Asian shares rose Thursday, buoyed by optimism that the U.S.-Japan tariff agreement will be followed by more trade deals. Japan's Nikkei 225 surged nearly 2% to 41,983.50. The Shanghai Composite Index added 0.4% to 3,595.58 while Hong Kong's Hang Seng index rose 0.4% to 25,631,08. South Korea's Kospi climbed 0.9% to 3,211.21 after central bank data showed Thursday that the country's second quarter GDP rose 0.6%, above expectations thanks to robust private consumption and exports. India's BSE Sensex edged 0.7% higher to 82,726.64 and Australia's S&P ASX 200 slid 0.1% to 8,729.20. 'Asian equities caught another updraft, rising for a sixth straight session, as whispers of broader trade accords scattered across the tape like migrating birds sensing the storm has passed,' Stephen Innes of SPI Asset Management wrote in a commentary. 'With the ink barely dry on the U.S.-Japan tariff truce — inked at a palatable 15% — traders are already scanning the horizon for the next deal to surface. Europe? Maybe. India? China? Everyone? Perhaps. But the mood is pure Electric Avenue,' he added. On Wednesday, U.S. stocks set more records following a trade deal between the world's No. 1 and No. 4 economies, one that would lower proposed tariffs on Japanese imports coming to the United States. The S&P 500 added 0.8% to its all-time high. The Dow Jones Industrial Average rallied 507 points, or 1.1%, and the Nasdaq composite climbed 0.6% to hit its own record. Stocks jumped even more in Tokyo on Wednesday, where the Nikkei 225 rallied 3.5% after President Donald Trump announced a trade framework that would place a 15% tax on imports coming from Japan. That's lower than the 25% rate that Trump had earlier said would kick in on Aug. 1. Trump has proposed stiff taxes on imports from around the world, which carry the double-edged risk of driving up inflation for U.S. households while slowing the economy. But many of Trump's tariffs are currently on pause, giving time to reach deals with other countries that could lower the tax rates. Trump also announced a trade agreement with the Philippines on Tuesday. So far, the U.S. economy has seemed to hold up OK despite the pressures on it. And tariffs already in place may be having less of an effect than expected, at least when it comes to the prices that U.S. households are paying at the moment. In other dealings on Thursday, U.S. benchmark crude oil added 22 cents to $65.47 per barrel. Brent crude, the international standard, rose 21 cents to $68.72 per barrel. The U.S. dollar fell to 146.03 against the Japanese yen from 146.51. The euro rose to $1.1781 from $1.1777.
Business Upturn
an hour ago
- Business Upturn
VA Tech Wabag wins Rs 2,332 crore order for mega desalination plant in Saudi Arabia
VA Tech Wabag, a leading Indian multinational in the water technology space, has secured a major international order from the Saudi Water Authority (SWA) for a massive desalination project in Yanbu, Saudi Arabia. Valued at approximately USD 272 million (SAR 1,019 million / ₹2,332 crore), the project involves the design, engineering, supply, construction, and commissioning of a 300 Million Litres per Day (MLD) Sea Water Reverse Osmosis (SWRO) mega desalination plant. This greenfield project will be developed along the Kingdom's west coast and is expected to be executed over a 30-month timeline from the effective date, which will be confirmed after formal contract signing. Wabag has received the Letter of Award and will now proceed with contract formalities. Once finalized, execution of the project will begin. This is an international order and does not involve any related party transactions. Neither Wabag's promoters nor group companies have any stake or interest in the awarding entity. Rohan Mittal, Head of Strategy and Business Growth for GCC, stated, 'We are immensely proud to have emerged successful in this prestigious project not just once, but twice. This repeat success underscores the strength of our technical competence, competitiveness and our deep-rooted capabilities in executing large and complex desalination projects. This prestigious project, aligns with and contributes to the ambitious goals of Saudi Vision 2030 and reinforces WABAG's global leadership in the desalination sector.' Ahmedabad Plane Crash Aman Shukla is a post-graduate in mass communication . A media enthusiast who has a strong hold on communication ,content writing and copy writing. Aman is currently working as journalist at
Business Upturn
an hour ago
- Business Upturn
Dr Reddy's stock: CLSA, Jefferies recommend sell, Morgan Stanley says hold — here's why
By Arunika Jain Published on July 24, 2025, 08:40 IST Top brokerages have delivered a mixed outlook on Dr. Reddy's Laboratories following its Q1FY26 results. While Jefferies and CLSA retained their Underperform ratings citing concerns over U.S. business momentum and gRevlimid tapering, Morgan Stanley maintained an Equal-Weight stance with a ₹1,298 target. CLSA: Cautious on U.S. growth taper CLSA kept an Underperform rating with a target of ₹1,120, saying Q1 earnings were in line with estimates. However, it expects the U.S. base business to be flat or grow at low single digits, and noted that gRevlimid sales could start tapering from Q3FY26. The potential launch of Semaglutide in Canada and India may partly offset this slowdown, CLSA added. Jefferies: Q1 miss, watching key launches Jefferies also retained an Underperform rating with a lower target of ₹1,100, citing a Q1 miss due to a decline in U.S. sales, particularly gRevlimid and the base business. SG&A and R&D expenses stayed elevated. However, Jefferies is watching two key pipeline catalysts: the approval of gOzempic in Canada and U.S. filing for Abatacept, which it believes could meaningfully contribute to revenue if launched on time. Morgan Stanley: Balanced view Morgan Stanley took a more neutral stance with an Equal-Weight rating and a target price of ₹1,298. It noted that Q1 revenue grew 11% YoY, but gross margins declined due to higher price erosion and lower operating leverage. EBITDA was in line, while PAT rose 2% YoY. Morgan Stanley believes the risk-reward remains balanced. Disclaimer: The brokerage views expressed above are solely those of the respective firms. This article does not constitute investment advice. Readers are advised to consult their financial advisor before making any investment decisions. Ahmedabad Plane Crash Arunika Jain, a graduate in Mass Communication, brings a fresh perspective to the world of journalism. Arunika has a passion for writing finance and corporate news at You can write to her at [email protected]
